Archive

Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program

-Recent results presented at the ICI Meeting in Israel- NASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 6, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today provided an update on the clinical experience with its Tiara™ transcatheter mitral valve.  Tiara™ is a novel transcatheter...

Read More

Neovasc and Boston Scientific Reach US$75 Million Agreement

- Boston Scientific acquires tissue processing capabilities and takes equity stake in Neovasc - NASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 2, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, has...

Read More

Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 28, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced it has received both regulatory and ethics committee approval to initiate the Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy.   TIARA II is...

Read More

Neovasc Announces Dismissal of Class Action Lawsuit

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 23, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today that the United States District Court for the District of Massachusetts granted the Company's motion to dismiss with prejudice in the case of Grobler v....

Read More

Neovasc Reports Third Quarter Results for 2016

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 14, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced financial results for the quarter ended September 30, 2016 (all figures in US dollars unless otherwise indicated). "While the Company has faced litigation headwinds, we remain committed...

Read More

Neovasc to Host Third Quarter 2016 Conference Call

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 7, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that it will release its financial results for the third quarter of 2016 on Monday, November 14, 2016, after markets close. The Company will subsequently hold...

Read More

Neovasc’s Tiara and Reducer Highlighted at TCT Presentations

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 2, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today its notable presentations at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium, the world's largest educational meeting specializing in interventional cardiovascular medicine held in Washington, DC. On...

Read More

Neovasc Announces Update in Litigation with CardiAQ

NASDAQ: NVCNTSX: NVC VANCOUVER, Nov. 1, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) reported today the findings of the Federal District Court regarding several post-trial motions stemming from a trial jury's verdict in May 2016.  CardiAQ filed suit against Neovasc in the...

Read More